The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Controversies and unanswered questions in smoldering myeloma and MGUS
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses controversies and unanswered questions in the management of the precursor diseases smoldering myeloma and monoclonal gammopathy of undetermined significance (MGUS). Dr Ghobrial highlights the need for clarification on definitions, risk stratification, and treatment options to optimize patient care. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There’s a lot of things that are exciting. I think now MGUS and smoldering myeloma are the hottest topic in multiple myeloma because there are so many controversies and so many questions to be asked. Are we treating the right population in smoldering myeloma? What is the definition of high-risk smoldering myeloma? Can we stratify them in a more accurate way? What are the best treatment options? Is there enough tomuzumab? Should we do more therapy? And what is the end goal here? Should we wait for biochemical progression or MRD negative disease or wait for patients to have end organ damage? And hopefully we will have answers to all of these, but right now we’re all as myeloma doctors and scientists trying to figure out what is the best answer for our patients...
There’s a lot of things that are exciting. I think now MGUS and smoldering myeloma are the hottest topic in multiple myeloma because there are so many controversies and so many questions to be asked. Are we treating the right population in smoldering myeloma? What is the definition of high-risk smoldering myeloma? Can we stratify them in a more accurate way? What are the best treatment options? Is there enough tomuzumab? Should we do more therapy? And what is the end goal here? Should we wait for biochemical progression or MRD negative disease or wait for patients to have end organ damage? And hopefully we will have answers to all of these, but right now we’re all as myeloma doctors and scientists trying to figure out what is the best answer for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen: Consultancy, Other: Speaker fees; GlaxoSmithKline: Consultancy; Standard Biotools: Other: Speaker fees; Aptitude Health: Consultancy; Pfizer: Consultancy, Other: Speaker fees; Takeda: Consultancy, Other: Speaker fees; Binding Site, part of Thermo Fisher Scientific: Consultancy; CurioScience: Consultancy, Other: Speaker fees; Huron Consulting: Consultancy; Janssen: Consultancy, Other: Speaker fees; Window Therapeutics: Consultancy; Menarini Silicon Biosystems: Consultancy, Other: Speaker fees; Bristol Myers Squibb: Consultancy, Other: Speaker fees; Adaptive: Consultancy; AbbVie: Consultancy; Vor Biopharma: Other: Speaker fees; Oncopeptides: Consultancy; Novartis: Consultancy; Sanofi: Consultancy; 10X Genomics: Consultancy; Regeneron: Consultancy, Other: Speaker fees; PreDICTA Bioscience: Consultancy, Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees, Other: Co-founder; Disc Medicine: Current equity holder in private company, Membership on an entity’s Board of Directors or advisory committees.
